Program
ATG-022
A development code.
Its studies are led by Antengene Biologics.
Furthest: phase 3, since Aug 25, 20263 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Antengene Biologics | 33 open or running | phase 3since Aug 25, 2026 | Jan 17, 2023 | Sep 30, 2027phase 2 · NCT07327229 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2023First study: phase 1 study in Advanced/Metastatic Solid TumorsFirst studyNCT05718895 · 156 planned · Australia, China
- Dec 5, 2025Phase 2 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07327229 · 132 planned · China
- Aug 25, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3 reachedNCT07795346 · 380 planned · China
Ahead
- Sep 30, 2027Primary completion: phase 2 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07327229
- Dec 30, 2027Primary completion: phase 1 study in Advanced/Metastatic Solid TumorsNCT05718895
- Dec 31, 2029Primary completion: phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07795346
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07795346Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Dec 31, 2029 | 380 |
| NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Sep 30, 2027 | 132 |
| NCT05718895Advanced/Metastatic Solid Tumors · Australia, China | 1 | Recruiting | Dec 30, 2027 | 156 |
How it is read
Names in the registry
- “ATG-022”, 3 entries
Codes read as this program: ATG022.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.